Applied DNA Sciences and Takis Biotech Announce
the Production of Neutralizing Antibodies
Against SARS-CoV-2 After DNA Vaccination in Animals
Beyond expectations, a single injection of DNA in mice induced antibodies that block the infection of cultured human cells by SARS-CoV-2.
The press release, from Stony Brook, N.Y. and Rome, Italy, about a vaccine against COVID-19 developed by Applied DNA Sciences (APDN) and its vaccine development partner Takis Biotech (“Takis”). In the joint press release, the firms announced that the first injections of the DNA vaccine candidates against the Spike protein (product of the S gene) of the SARS-CoV-2 virus, cause of the COVID-19 disease, have produced neutralizing antibodies in test animals.
The studies were completed at the renowned Lazzaro Spallanzani (“Spallanzani”) National Institute for Infectious Diseases in Rome.